Acute inflammation and hematological response in Nile tilapia fed supplemented diet with natural extracts of propolis and Aloe barbadensis.

This study evaluated the acute inflammatory response induced by carrageenin in the swim bladder of Nile tilapia supplemented with the mixture of natural extracts of propolis and Aloe barbadensis (1:1) at a concentration of 0.5%, 1% and 2% in diet during 15 days. Thirty-six fish were distributed into four treatments with three replicates: fish supplemented with 0.5% of admix of extracts of propolis and Aloe (1:1) injected with 500 µg carrageenin; fish supplemented with 1% of admix of extracts of propolis and Aloe (1:1) injected with 500 µg carrageenin; fish supplemented with 2% of admix of extracts of propolis and Aloe (1:1), injected with 500 µg carrageenin and unsupplemented fish injected with 500 µg carrageenin. Six hours after injection, samples of blood and exudate from the swim bladder of fish were collected. It was observed an increase in the leukocyte count in the swim bladder exudate of fish supplemented with extracts of propolis and Aloe injected with carrageenin. The most frequent cells were macrophages followed by granular leukocytes, thrombocytes and lymphocytes. Supplementation with propolis and Aloe to 0.5% caused a significant increase in the number of cells on the inflammatory focus mainly macrophages, cells responsible for the phagocytic activity in tissues, agent of innate fish immune response.

Acute inflammation and hematological response in Nile tilapia fed supplemented diet with natural extracts of propolis and Aloe barbadensis / Inflamação aguda e resposta hematológica em tilápias do Nilo alimentadas com extratos naturais de própolis e Aloe barbadensis suplementados na dieta

This study evaluated the acute inflammatory response induced by carrageenin in the swim bladder of Nile tilapia supplemented with the mixture of natural extracts of propolis and Aloe barbadensis (1:1) at a concentration of 0.5%, 1% and 2% in diet during 15 days. Thirty-six fish were distributed into four treatments with three replicates: fish supplemented with 0.5% of admix of extracts of propolis and Aloe (1:1) injected with 500 µg carrageenin; fish supplemented with 1% of admix of extracts of propolis and Aloe (1:1) injected with 500 µg carrageenin; fish supplemented with 2% of admix of extracts of propolis and Aloe (1:1), injected with 500 µg carrageenin and unsupplemented fish injected with 500 µg carrageenin. Six hours after injection, samples of blood and exudate from the swim bladder of fish were collected. It was observed an increase in the leukocyte count in the swim bladder exudate of fish supplemented with extracts of propolis and Aloe injected with carrageenin. The most frequent cells were macrophages followed by granular leukocytes, thrombocytes and lymphocytes. Supplementation with propolis and Aloe to 0.5% caused a significant increase in the number of cells on the inflammatory focus mainly macrophages, cells responsible for the phagocytic activity in tissues, agent of innate fish immune response.

Este estudo avaliou a resposta inflamatória aguda induzida por carragenina na bexiga natatóriade tilápia do Nilo suplementada com a mistura dos extratos naturais de própolis e Aloe barbadensis (1:1), nas concentrações de 0,5%, 1% e 2% na dieta durante o período de 15 dias. Trinta e seis peixes foram distribuídos em quatro tratamentos com três repetições: peixes suplementados com 0,5% da mistura dos extratos de própolis e Aloe (1:1) injetados na bexiga natatória com 500 µg de carragenina; peixes suplementados com 1% da mistura dos extratos de própolis e Aloe (1:1) injetados na bexiga natatória com 500 µg de carragenina; peixes suplementados com 2% da mistura dos extratos de própolis e Aloe (1:1) injetados na bexiga natatória com 500 µg de carragenina e peixes não suplementados injetados na bexiga natatória com 500 µg de carragenina. Seis horas após as injeções foram coletadas amostras de sangue e exsudato da bexiga natatória dos peixes. Foi observado aumento na contagem de leucócitos no exsudato da bexiga natatória de peixes suplementados com os extratos de própolis e Aloe injetados com carragenina. As células mais frequentes foram os macrófagos seguidos pelos leucócitos granulares, trombócitos e linfócitos. A suplementação com própolis e Aloe a 0,5% provocou aumento significativo no número de células no foco inflamatório, principalmente dos macrófagos, células responsáveis pela atividade fagocitária nos tecidos, agente da resposta imune inata nos peixes.

Acute inflammation and hematological response in Nile tilapia fed supplemented diet with natural extracts of propolis and Aloe barbadensis / Inflamação aguda e resposta hematológica em tilápias do Nilo alimentadas com extratos naturais de própolis e Aloe barbadensis suplementados na dieta

This study evaluated the acute inflammatory response induced by carrageenin in the swim bladder of Nile tilapia supplemented with the mixture of natural extracts of propolis and Aloe barbadensis (1:1) at a concentration of 0.5%, 1% and 2% in diet during 15 days. Thirty-six fish were distributed into four treatments with three replicates: fish supplemented with 0.5% of admix of extracts of propolis and Aloe (1:1) injected with 500 µg carrageenin; fish supplemented with 1% of admix of extracts of propolis and Aloe (1:1) injected with 500 µg carrageenin; fish supplemented with 2% of admix of extracts of propolis and Aloe (1:1), injected with 500 µg carrageenin and unsupplemented fish injected with 500 µg carrageenin. Six hours after injection, samples of blood and exudate from the swim bladder of fish were collected. It was observed an increase in the leukocyte count in the swim bladder exudate of fish supplemented with extracts of propolis and Aloe injected with carrageenin. The most frequent cells were macrophages followed by granular leukocytes, thrombocytes and lymphocytes. Supplementation with propolis and Aloe to 0.5% caused a significant increase in the number of cells on the inflammatory focus mainly macrophages, cells responsible for the phagocytic activity in tissues, agent of innate fish immune response.(AU)

Este estudo avaliou a resposta inflamatória aguda induzida por carragenina na bexiga natatóriade tilápia do Nilo suplementada com a mistura dos extratos naturais de própolis e Aloe barbadensis (1:1), nas concentrações de 0,5%, 1% e 2% na dieta durante o período de 15 dias. Trinta e seis peixes foram distribuídos em quatro tratamentos com três repetições: peixes suplementados com 0,5% da mistura dos extratos de própolis e Aloe (1:1) injetados na bexiga natatória com 500 µg de carragenina; peixes suplementados com 1% da mistura dos extratos de própolis e Aloe (1:1) injetados na bexiga natatória com 500 µg de carragenina; peixes suplementados com 2% da mistura dos extratos de própolis e Aloe (1:1) injetados na bexiga natatória com 500 µg de carragenina e peixes não suplementados injetados na bexiga natatória com 500 µg de carragenina. Seis horas após as injeções foram coletadas amostras de sangue e exsudato da bexiga natatória dos peixes. Foi observado aumento na contagem de leucócitos no exsudato da bexiga natatória de peixes suplementados com os extratos de própolis e Aloe injetados com carragenina. As células mais frequentes foram os macrófagos seguidos pelos leucócitos granulares, trombócitos e linfócitos. A suplementação com própolis e Aloe a 0,5% provocou aumento significativo no número de células no foco inflamatório, principalmente dos macrófagos, células responsáveis pela atividade fagocitária nos tecidos, agente da resposta imune inata nos peixes.(AU)

Glutamine supplementation prevents collagen expression damage in healthy urinary bladder caused by radiotherapy.

OBJECTIVE: Patients who have had pelvic radiotherapy as part of their cancer therapy may develop subsequent urinary bladder effects such as hyperactive bladder, incontinence, and dysuria. Therefore, the goal of this study was to evaluate whether glutamine supplementation could prevent collagen expression damage in healthy urinary bladder caused by radiotherapy. METHODS: Fifteen adult Wistar rats were separated into a control group that received food and water ad libitum (C group), an irradiated group that received a single pelvic radiation dose of 1164 cGy (I group), and an irradiated group supplemented with l-glutamine every day during the entire experimental period (0.65 g/kg of body weight; I+G group). All animals were sacrificed 15 d after irradiation. The extracellular matrix and muscle were quantified by a morphometric method. Picro Sirius Red was used to visualize the different collagen types. Reverse transcription-polymerase chain reaction and immunohistochemistry were used to determine collagen type I and III expressions. RESULTS: The extracellular matrix (C group 36.84±4.37, I group 31.64±5.00, I+G group 35.53±2.60, P=0.0001), muscle (C group 36.43±6.15, I group 29.39±7.08, I+G group 31.38±3.14, P=0.0001), and gene expressions of collagen type I (C group 1.067±0.31, I group 0.579±0.17, I+G group 1.816±0.66, P=0.0009) and type III (C group 0.99±0.28, I group 0.54±0.13, I+G group 1.07±0.28, P=0.0080) were decreased in the I group. Apart from muscle, glutamine supplementation prevented these alterations. Immunohistochemistry and Picro Sirius Red showed similar results. CONCLUSION: Supplementation with l-glutamine seems to prevent bladder wall damage in relation to extracellular matrix volumetric density and collagen expression. These results suggest that glutamine supplementation could be efficient in protecting healthy tissues from the adverse effects of radiotherapy.

Bleeding during oral anticoagulant therapy: warning against a greater hazard.

BACKGROUND: Bleeding is one of the main concerns in patients undergoing oral anticoagulation therapy. OBJECTIVE: To investigate the determinant causes of bleeding in patients undergoing oral anticoagulant therapy. METHODS: A total of 360 patients with atrial fibrillation (AF) undergoing oral anticoagulant (ACo) therapy, with a target INR of 2.0-3.5, were followed prospectively for a period of 48 +/- 7.2 months. The patients were evaluated on average every 30 days and were investigated regarding the presence of associated pathology that could lead to bleeding. RESULTS: A total of 338 patients participated in the present study. Of these, 210 (62.13%) were females. Mitral stenosis was present in 218 patients (64.4%), a mitral biological prosthesis in 64 (18.9%) and mitral valve failure in 56 (16.5%) patients. Bleeding occurred in 65 patients (19.2%), being severe in 7 (10%) patients. In 38/65 patients, a new associated disease was identified, which facilitated bleeding. An associated disease was identified in 100% of the patients with bleeding within the therapeutic range, against 49.05% of associated disease diagnosis in those with an INR > 3.5 (p=0.001). CONCLUSION: The diagnosis of a local disease associated to the bleeding was frequent among those patients undergoing oral anticoagulant therapy (58.5%). There was an association between bleeding with an INR within the therapeutic range (INR=2.0-3.5) and the diagnosis of a pathology predisposing to bleeding (p<0.001). It is mandatory to investigate the cause of bleeding in patients undergoing oral anticoagulant therapy, especially if the INR is within the therapeutic range.

Sangramento durante a anticoagulação oral: alerta sobre um mal maior / Sangrado durante la anticoagulación oral: alerta sobre un mal mayor / Bleeding during oral anticoagulant therapy: warning against a greater hazard

FUNDAMENTO: Sangramento é uma das grandes preocupações em pacientes sob anticoagulação oral. OBJETIVO: Investigar causas determinantes do sangramento em usuários de anticoagulante oral. MÉTODOS: Foram acompanhados prospectivamente, por 48 ± 7,2 meses, 360 pacientes com fibrilação atrial (FA), todos em uso de anticoagulante oral (ACo) com INR-alvo de 2,0-3,5, avaliados em média a cada 30 dias. Os pacientes foram investigados quanto à presença de patologia associada que levasse a sangramento. RESULTADOS: Participaram deste estudo 338 pacientes. Desses, 210 (62,13 por cento) eram do sexo feminino. A estenose mitral estava presente em 218 pacientes (64,4 por cento), a prótese biológica mitral em 64 (18,9 por cento) e a insuficiência da valva mitral em 56 (16,5 por cento). O sangramento ocorreu em 65 pacientes (19,2 por cento) e de forma grave em 7 (10 por cento). Em 38/65 pacientes (58,5 por cento), identificou-se nova doença associada, facilitadora do sangramento. Em 100 por cento dos pacientes com sangramento na faixa terapêutica, foi encontrada doença associada, contra 49,05 por cento de diagnóstico de doenças associadas naqueles com INR > 3,5 (p = 0,001). CONCLUSÃO: O diagnóstico de doença local associada ao sangramento foi frequente entre os medicados com anticoagulante oral (58,5 por cento). Houve associação entre sangramento com INR na faixa terapêutica (INR 2,0-3,5) e diagnóstico de patologia predisponente a sangramento (p < 0,001). Em pacientes em uso de anticoagulante oral que apresentam sangramento, é mandatória a investigação da causa, sobretudo se a INR estiver na faixa terapêutica.

BACKGROUND: Bleeding is one of the main concerns in patients undergoing oral anticoagulation therapy. OBJECTIVE: To investigate the determinant causes of bleeding in patients undergoing oral anticoagulant therapy. METHODS: A total of 360 patients with atrial fibrillation (AF) undergoing oral anticoagulant (ACo) therapy, with a target INR of 2.0-3.5, were followed prospectively for a period of 48 ± 7.2 months. The patients were evaluated on average every 30 days and were investigated regarding the presence of associated pathology that could lead to bleeding. RESULTS: A total of 338 patients participated in the present study. Of these, 210 (62.13 percent) were females. Mitral stenosis was present in 218 patients (64.4 percent), a mitral biological prosthesis in 64 (18.9 percent) and mitral valve failure in 56 (16.5 percent) patients. Bleeding occurred in 65 patients (19.2 percent), being severe in 7 (10 percent) patients. In 38/65 patients, a new associated disease was identified, which facilitated bleeding. An associated disease was identified in 100 percent of the patients with bleeding within the therapeutic range, against 49.05 percent of associated disease diagnosis in those with an INR > 3.5 (p=0.001). CONCLUSION: The diagnosis of a local disease associated to the bleeding was frequent among those patients undergoing oral anticoagulant therapy (58.5 percent). There was an association between bleeding with an INR within the therapeutic range (INR=2.0-3.5) and the diagnosis of a pathology predisposing to bleeding (p<0.001). It is mandatory to investigate the cause of bleeding in patients undergoing oral anticoagulant therapy, especially if the INR is within the therapeutic range.

FUNDAMENTO: El sangrado es una de las grandes preocupaciones en pacientes bajo anticoagulación oral. OBJETIVO: Investigar causas determinantes del sangrado en usuarios de anticoagulante oral. MÉTODOS: Se realizó el seguimiento, prospectivamente, por 48 ± 7,2 meses, de 360 pacientes con fibrilación atrial (FA), todos en uso de anticoagulante oral (ACo) con INR-objetivo de 2,0-3,5, evaluados en promedio cada 30 días. Los pacientes se investigaron sobre la presencia de patología asociada que llevara al sangrado. RESULTADOS: Participaron en este estudio 338 pacientes. De ellos, 210 (62,13 por ciento) eran del sexo femenino. La estenosis mitral estaba presente en 218 pacientes (64,4 por ciento), la prótesis biológica mitral en 64 (18,9 por ciento) y la insuficiencia de la válvula mitral en 56 (16,5 por ciento). El sangrado ocurrió en 65 pacientes (19,2 por ciento) y de forma grave en 7 (10 por ciento). En 38/65 pacientes (58,5 por ciento), se identificó nueva enfermedad asociada, facilitadora del sangrado. En el 100 por ciento de los pacientes con sangrado en el intervalo terapéutico, se encontró enfermedad asociada, contra el 49,05 por ciento de diagnóstico de enfermedades asociadas en aquellos con INR > 3,5 (p = 0,001). CONCLUSIÓN: El diagnóstico de enfermedad local asociada al sangrado fue frecuente entre los medicados con anticoagulante oral (58,5 por ciento). Hubo asociación entre sangrado con INR en el intervalo terapéutico (INR 2,0-3,5) y diagnóstico de patología predisponente a sangrado (p < 0,001). En pacientes en uso de anticoagulante oral que presentan sangrado, es indispensable la investigación de la causa, sobre todo si la INR está en el intervalo terapéutico.

Anti-inflammatory effect of the latex from Calotropis procera in three different experimental models: peritonitis, paw edema and hemorrhagic cystitis.

Latex from Calotropis procera is widely used in folk medicine as a rich source of biologically active compounds capable of promoting diverse benefits such as control of dermal fungal infections, antimicrobial activities and pain relief among other useful properties. The aim of this work was to characterize the anti-inflammatory effect of a non-dialysable protein fraction recovered from the rubber-free latex using three different experimental models when administrated intravenously. In vivo neutrophil migration induced by carrageenin (500 microg) was severely inhibited by doses of latex proteins reaching maximum inhibition (80%) at 100 mg/kg. Paw edema exacerbated by the effect of carrageenin was almost completely suppressed after 4 hours and was controlled within the first hour following latex protein administration. However, the same latex fraction was completely unable to control the paw edema invoked with dextran stimulation (400 microg), suggesting that the inhibitory effect of the latex is likely to be cell-mediated. Iphosphamide-induced vesical edema in mice was also largely prevented by the latex protein fraction. These results indicate that an effect similar to that of mesna, the classical drug used for this purpose, is operative. Our findings suggest that the sample tested seems to act over a wide spectrum as a novel anti-inflammatory agent. The results also suggest that the active molecules are of a proteinaceous nature despite the presence of numerous secondary metabolites naturally occurring in the C. procera latex.